RadNet (NASDAQ:RDNT) and Celcuity (NASDAQ:CELC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, dividends, institutional ownership and profitability.
Institutional and Insider Ownership
61.4% of RadNet shares are owned by institutional investors. Comparatively, 15.2% of Celcuity shares are owned by institutional investors. 7.6% of RadNet shares are owned by insiders. Comparatively, 43.5% of Celcuity shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This table compares RadNet and Celcuity’s net margins, return on equity and return on assets.
This is a summary of recent ratings for RadNet and Celcuity, as provided by MarketBeat.com.
RadNet presently has a consensus price target of $14.67, suggesting a potential upside of 46.23%. Celcuity has a consensus price target of $35.50, suggesting a potential upside of 63.14%. Given Celcuity’s higher possible upside, analysts plainly believe Celcuity is more favorable than RadNet.
Risk & Volatility
RadNet has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Comparatively, Celcuity has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500.
Earnings and Valuation
This table compares RadNet and Celcuity’s top-line revenue, earnings per share and valuation.
RadNet has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than RadNet, indicating that it is currently the more affordable of the two stocks.
RadNet beats Celcuity on 10 of the 14 factors compared between the two stocks.
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the imaging industry, including picture archiving communications systems; and provides teleradiology services for remote interpretation of images on behalf of radiology groups, hospitals, and imaging center customers. As of December 31, 2017, it operated 297 facilities directly or indirectly through joint ventures with hospitals in California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1981 and is headquartered in Los Angeles, California.
Celcuity Inc., a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the response rates of cancer patients treated with targeted therapies in the United States. The company is developing CELx tests to diagnose two new sub-types of HER2-negative breast cancer. It is also developing CELx tests to diagnose 14 new potential cancer sub-types in breast, lung, colon, ovarian, kidney, bladder, and hematological cancers. The company was founded in 2012 and is headquartered in Minneapolis, Minnesota.